- Home
- JAGX
JAGX
Jaguar Health Inc.
as 11-15-2024 12:36pm EST
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 9.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 304.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.90 - $30.84 | Next Earning Date: | 11-13-2024 |
| Revenue: | $10,480,000 | Revenue Growth: | -2.25% |
| Revenue Growth (this year): | 32.33% | Revenue Growth (next year): | 43.63% |
Latest Jaguar Health Inc. News
JAGX Breaking Stock News: Dive into JAGX Ticker-Specific Updates for Smart Investing
GuruFocus.com
a day ago
Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
ACCESSWIRE
2 days ago
Jaguar Health Reports Third Quarter 2024 Financial Results
ACCESSWIRE
4 days ago
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
ACCESSWIRE
9 days ago
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
ACCESSWIRE
11 days ago
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
ACCESSWIRE
17 days ago
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
ACCESSWIRE
a month ago
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
ACCESSWIRE
a month ago
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare JAGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAGX Jaguar Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.